Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes
Article 2014 en
Authors
ZY
Zenas Z N Yiu
RW
Richard B. Warren
UM
Ulrich Mrowietz
Abstract
1 min read
The effects of conventional systemic therapies for psoriasis on pregnancy outcomes, lactation, male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide clinician and patient. In this study, we review the safety profile of the commonly used conventional systemic therapies used for psoriasis in individuals of reproductive potential. Safety data are derived from large-scale registries, adverse-event reporting databases, clinical trials and case reports. We assess the effect of each therapy on adverse pregnancy outcomes, including congenital malformations, and lactation with maternal administration. We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.
Wolfram Sterry, Juliet N. Barker, Wolf‐Henning Boehncke, J.D. Bos, Sergio Chimenti, Enno Christophers, M. de la Brassinne, Christopher Em Griffiths, Andreas Katsambas, Knud Kragballe, Charles Lynde, Alan Menter, J.‐P. Ortonne, Kim Papp, Jörg C. Prinz, Berthold Rzany, J.R. Rönnevig, J.‐H. Saurat, Mona Ståhle, Fernando Stengel, P.C.M. van de Kerkhof, John J. Voorhees
K.J. Mason, S. Williams, Zenas Z N Yiu, Kathleen McElhone, Darren M. Ashcroft, C. Elise Kleyn, Zarif K. Jabbar‐Lopez, Caroline Owen, Nick J. Reynolds, Catherine Smith, Nina Wilson, Richard B. Warren, Christopher Em Griffiths
Discussion(0)
No comments yet. Be the first to comment.